Max Hodak’s New Mission: The 'Biohybrid' Brain Link

Max Hodak, who co-founded Neuralink with Elon Musk, is taking a different path with his new startup, Science Corporation. The company is preparing for human clinical trials of its biohybrid Brain-Computer Interface (BCI: a technology that translates brain activity into digital commands).

Dr. Murat Günel, chair of Neurosurgery at Yale Medical School, has joined as a scientific adviser. His role will be to surgically place the first sensors—which will eventually combine lab-grown neurons with high-tech electronics—into the brains of patients.

Why Biological Integration Beats Metal Probes

Traditional BCIs use metal electrodes that are inserted directly into the brain. Over time, this can lead to scarring and decreased performance, much like how a foreign object might cause irritation in soft tissue.

Science Corporation's approach is different. They are developing a "biohybrid" sensor that uses lab-grown neurons to act as a bridge between machine and mind. This method aims to create a more natural and lasting connection with the human nervous system.

"The idea of using natural connections through neurons and creating a biological interface between the electronics and the human brain is genius." - Dr. Murat Günel

A Safer, Surface-Level Design

1. Resting on the Cortex

Unlike Neuralink, which goes deep into brain tissue, Science’s sensor is designed to sit on top of the brain's surface. The device, which is roughly the size of a pea, contains 520 electrodes that record activity without the need for invasive needles.

2. Clinical Trial Strategy

The team plans to test the device on patients who already require brain surgery, such as stroke victims needing cranial procedures to manage brain swelling (edema). This allows researchers to evaluate safety without unnecessary additional risks.

  • Safety: Minimal risk of brain tissue damage compared to invasive probes.
  • Precision: High-density electrodes packed into a tiny area for clear data.
  • Integration: Designed to eventually merge biological neurons with electronic pulses of light.

New Hope for Parkinson's Treatment

Dr. Günel believes this technology could go beyond controlling computers and actually treat neurological disorders. For Parkinson's disease—a condition that gradually takes away body control—current treatments only mask symptoms with electricity.

A biohybrid system could potentially stop the disease's progression. By transplanting healthy cells back into the brain and protecting them with an electronic circuit, the device might repair the damaged paths that cause the disease.

While the vision is grand, the road ahead is long. Dr. Günel estimates that human trials might realistically begin around 2027. If successful, this could pave the way for "human enhancement," adding entirely new senses or capabilities to the body.